Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
- Ninety patients suffering from active rheumatoid arthritis despite continued treatment
with methotrexate will be evaluated for improvement of disease activity when taking
GLPG0634 (4 different doses will be evaluated) or matching placebo for 4 weeks.
- During the course of the study, patients will also be examined for any side effects that
may occur, and the amount of GLPG0634 present in the blood as well as the effects of
GLPG0634 on disease- and mechanism of action-related parameters in the blood will be
determined.